- Home
- BZFD vs RVPHW Comparison
BZFD vs RVPHW Comparison
Compare BZFD & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZFD
- RVPHW
- Stock Information
- Founded
- BZFD 2006
- RVPHW N/A
- Country
- BZFD United States
- RVPHW United States
- Employees
- BZFD N/A
- RVPHW 15
- Industry
- BZFD Movies/Entertainment
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- BZFD Consumer Discretionary
- RVPHW Health Care
- Exchange
- BZFD Nasdaq
- RVPHW Nasdaq
- Market Cap
- BZFD N/A
- RVPHW N/A
- IPO Year
- BZFD N/A
- RVPHW 2018
- Fundamental
- Price
- BZFD $2.70
- RVPHW $0.10
- Analyst Decision
- BZFD
- RVPHW
- Analyst Count
- BZFD 0
- RVPHW 0
- Target Price
- BZFD N/A
- RVPHW N/A
- AVG Volume (30 Days)
- BZFD 343.6K
- RVPHW N/A
- Earning Date
- BZFD 10-31-2024
- RVPHW N/A
- Dividend Yield
- BZFD N/A
- RVPHW N/A
- EPS Growth
- BZFD N/A
- RVPHW N/A
- EPS
- BZFD N/A
- RVPHW N/A
- Revenue
- BZFD $227,328,000.00
- RVPHW N/A
- Revenue This Year
- BZFD $35.96
- RVPHW N/A
- Revenue Next Year
- BZFD $4.81
- RVPHW N/A
- P/E Ratio
- BZFD N/A
- RVPHW N/A
- Revenue Growth
- BZFD N/A
- RVPHW N/A
- 52 Week Low
- BZFD $0.64
- RVPHW N/A
- 52 Week High
- BZFD $4.56
- RVPHW N/A
- Technical
- Relative Strength Index (RSI)
- BZFD 51.06
- RVPHW N/A
- Support Level
- BZFD $2.59
- RVPHW N/A
- Resistance Level
- BZFD $2.81
- RVPHW N/A
- Average True Range (ATR)
- BZFD 0.11
- RVPHW 0.00
- MACD
- BZFD -0.00
- RVPHW 0.00
- Stochastic Oscillator
- BZFD 38.60
- RVPHW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.